financetom
Business
financetom
/
Business
/
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing
Mar 7, 2024 2:09 PM

04:46 PM EST, 03/07/2024 (MT Newswires) -- Stephen P. Robertson, Executive Vice President, General Counsel, on March 06, 2024, sold 57,745 shares in Aurinia Pharmaceuticals ( AUPH ) for $323,372. Following the Form 4 filing with the SEC, Robertson has control over a total of 443,824 shares of the company, with 443,824 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1600620/000160062024000034/xslF345X03/wk-form4_1709847708.xml

Price: 5.5, Change: +0.05, Percent Change: +0.92

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Yes! Communities Explores Potential IPO in 2025
Market Chatter: Yes! Communities Explores Potential IPO in 2025
Dec 6, 2024
04:34 PM EST, 12/06/2024 (MT Newswires) -- Yes! Communities, a US manufactured-housing operator backed by Singapore's sovereign wealth fund GIC, is mulling a 2025 initial public offering to raise over $1 billion, Bloomberg reported Friday, citing sources. Yes! is collaborating with Goldman Sachs (GS) and plans to bring on additional underwriters in the coming months. However, no final decisions have...
BioAge discontinues mid-stage trial of obesity drug
BioAge discontinues mid-stage trial of obesity drug
Dec 6, 2024
Dec 6 (Reuters) - BioAge Labs ( BIOA ) said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's ( LLY ) tirzepatide for the treatment of obesity. ...
Cava Group Insider Sold Shares Worth $9,483,766, According to a Recent SEC Filing
Cava Group Insider Sold Shares Worth $9,483,766, According to a Recent SEC Filing
Dec 6, 2024
04:42 PM EST, 12/06/2024 (MT Newswires) -- Theodoros Xenohristos, Director, on December 04, 2024, sold 65,000 shares in Cava Group ( CAVA ) for $9,483,766. Following the Form 4 filing with the SEC, Xenohristos has control over a total of 359,846 shares of the company, with 359,846 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024050238/xslF345X05/wk-form4_1733520949.xml ...
Organigram Wants To Become Canada's Largest Cannabis Company By Market Share Via $71M Acquisition Deal
Organigram Wants To Become Canada's Largest Cannabis Company By Market Share Via $71M Acquisition Deal
Dec 6, 2024
Organigram Holdings Inc. ( OGI ) announced the acquisition of 100% of Motif Labs Ltd. for CA$90 million ($64 million), comprising of CA$50 million in cash and CA$40 million in Organigram ( OGI ) common shares, based on a 30-day trading VWAP of $2.321 on the TSX. An additional CA$10 million contingent consideration is payable in shares, conditional on achieving...
Copyright 2023-2026 - www.financetom.com All Rights Reserved